Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.
Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.
Note: This interview took place prior to the June 30, 2022, end of the OCM.
Transcript
What do you hope or expect practices will continue to do even after the OCM ends?
I think the things, to me, that were important: I like our standardized treatment plans. I find them to be a nice teaching tool for the patient to explain their diagnosis, their prognosis. I hand it to them. I hand them a drug handout. They go home, they share it with their family. It's a nice way for them to be able to go home and study the information and think about it. Also, sometimes they forget what we tell them, so it’s helpful for that aspect.
I think the patient outreach—like calling patients after treatments—I think that should stick around. I think one of our big wins was being able to cut the turnaround time on getting patient calls answered. I think that's a big win we need to keep.
I think there are a lot of improvements that were made—our depression screenings, our distress screenings increased—and those are things we really need to keep doing going forward.
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More